DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation
Journal of the American Chemical Society · 20.08.2025 · 147 (33) · 29742-29755
DOI: 10.1021/jacs.5c04918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 07.07.2025. Verfasst von Rong Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Molecular Sciences, Arizona State University, Tempe, Arizona 85281, United States. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin D1, Cyclin-Dependent Kinase 6, Proteolysis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, Division of Materials Research.
Abstract (Originalsprache)
Constraining proximity-based drugs, such as proteolysis targeting chimeras (PROTACs), into their bioactive conformation can significantly impact their selectivity and potency. However, traditional methods for achieving this often involve complex and time-consuming synthetic procedures. Here, we introduced an alternative approach by demonstrating DNA-templated spatially controlled PROTACs (DTACs), which leverage the programmability of nucleic acid-based self-assembly for efficient synthesis and offer precise control over inhibitors' spacing and orientation. The resulting constructs revealed distance- and orientation-dependent selectivity and degradation potency for the Cyclin D1-CDK4/6 protein complex in cancer cells. Notably, the optimal construct DTAC-V1 demonstrated unprecedented synchronous degradation of the entire Cyclin D1-CDK4/6 complex, leading to robust G1-phase cell cycle arrest and effective inhibition of cancer cell proliferation. Furthermore, in a xenograft mouse model, DTAC-V1 exhibited potent therapeutic efficacy by effectively degrading Cyclin D1-CDK4/6 and suppressing tumor growth, underscoring its potential as an anticancer agent. Overall, our findings demonstrate the feasibility of DTAC as a rapid, scalable, and modular platform for the spatial control of functional inhibitors for optimal effectiveness, making it a promising method for proximity-based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Molecular Sciences, Arizona State University, Tempe, Arizona 85281, United States.
- Center for Molecular Design and Biomimetics at the Biodesign Institute, Arizona State University, Tempe, Arizona 85281, United States.
ORCID-Profile: Petr Šulc
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- Division of Materials Research
Zitieren
APA
Zheng, R., Prasad, A., Satyabola, D., Xu, Y., Roy, S., Yan, Y., Šulc, P., & Yan, H. (2025). DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation. Journal of the American Chemical Society, 147(33), 29742-29755. https://doi.org/10.1021/jacs.5c04918
Vancouver
Zheng R, Prasad A, Satyabola D, Xu Y, Roy S, Yan Y, et al. DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation. Journal of the American Chemical Society. 2025;147(33):29742-29755. doi:10.1021/jacs.5c04918
BibTeX
@article{Zheng2025,
author = {Zheng, Rong and Prasad, Abhay and Satyabola, Deeksha and Xu, Yang and Roy, Subhajit and Yan, Yichen and Šulc, Petr and Yan, Hao},
title = {DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation},
journal = {Journal of the American Chemical Society},
year = {2025},
volume = {147},
number = {33},
pages = {29742--29755},
doi = {10.1021/jacs.5c04918}
}
EUVIMED